Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 22

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 22
---
 consists primarily of income earned on our cash and cash equivalent accounts, the balances of which were lower
during the three months ended June 30, 2025 compared to the three months ended June 30, 2024.

4

Six
months ended June 30, 2025 compared to six months ended June 30, 2024

The
following tables set forth our results of operations for the six months ended June 30, 2025 and 2024 and the relative dollar change between
the two periods.

    Six months ended  

    June 30,  
    Change 

    2025  
    2024  
    ($)  
    % 
  
    Operating expenses: 

    Research and development 
    $4,977,954  
    $3,305,115  
    $1,672,839  
     50.6%
  
    General and administrative 
     4,051,368  
     4,747,009  
     (695,641) 
     (14.7)%

    Total operating expenses 
     9,029,322  
     8,052,124  
     977,198  
     12.1%

    Loss from operations 
     (9,029,322) 
     (8,052,124) 
     (997,198) 
     12.1%

    Other income, net 
     55,676  
     230,180  
     (174,504) 
     (75.8)%
  
    Change in fair value of convertible promissory notes 
     (787,703) 
     -  
     (787,703) 
     - 

    Net loss 
    $(9,761,349) 
    $(7,821,944) 
    $(1,939,405) 
     24.8%
  
    Net loss attributable to common stockholders per share, basic and diluted 
    $(18.09) 
    $(25.79) 
    $7.70  
     (29.9)%
  
    Weighted average number of shares used in calculating net loss per share, basic and diluted 
     539,538  
     303,336  

Research
and Development Expenses

Research
and development expenses were approximately $5.